These treatments help one’s immune system to find and attack cancer cells the same way it attacks bacteria and viruses. It uses substances made up of white blood cells, organs and tissues of the lymph system to improve or restore immune system function.

Immunotherapy can work by maximizing the immune system to prevent or slow down the growth of cancer and reduce the probability of spreading. Some examples of immunotherapy include Natural Killer Cell therapy, Cancer vaccines (prophylactic or therapeutic) and Cytotoxic T-cell therapy.

Benefits of Immunotherapy are as follows:

• Support Other Treatments: Other therapies, such as chemotherapy, may work better if applied in tandem with immunotherapy.

• Effective When Other Treatments Aren’t: Certain cancers, such as skin cancer, don’t respond well to chemotherapy or radiation but may respond well to immunotherapy.

• Fewer Side Effects: Because it targets only your immune system, you may experience fewer side effects.

• Cancer Less Likely to Return: Your immune system learns to go after cancer cells if they return (immune-memory).

Natural Killer (NK) Cells

The functions of the organ systems in the body are all interconnected. To clearly understand how health issues are co-related, you need to know more about organ functions. Understanding the effects of treatment through Natural Killer cells (NK cells) for immunity restoration and cancer management will enhance one’s understanding of how beneficial this treatment can be for cancer sufferers and those who are keen on great health.

Immunity and cell degeneration

The body degenerates due to immunity dysfunction. Aside from resistance to microorganisms and cancer cells, the immunity controls the metabolism. A dysfunctional immunity leads to a degenerating metabolism. As a result, cells deteriorate, mutate or die.

White blood cells are generated from bone marrow stromal cells which may have deceased or degenerated over the years. When white blood cells, especially NK cells, work with less efficiency, the chances of illness and infection increases. Therefore, the figures for severe infection and cancer are high among the elderly. As we know, everyone grows old but aging gracefully in good health is the ultimate goal. Thus, it is extremely important to maintain a strong immune system.

Signs of deficient immunity and aging white blood cells

NK Cell activity test and immunity test can detect the efficiency of white blood cells. This at the same time also reflects the function of the immunity. Therefore, we can conclude that a less effective immunity is a sign of degenerative white blood cells.

Advantages of a strong immune system

Rejuvenated immune system raises the quality of life of the elderly and cancer sufferers. It aims to strengthen the immune system by resisting both microorganisms and cancer cells plus supports the self-healing process. The immune system is linked with the self-healing process, metabolism and even dead cell elimination.

On the other hand, a dysfunctional immune system is associated with cancer, overactive immune system, autoimmunity and other diseases, such as Parkinson’s disease, Alzheimer’s disease and more. So a fortified immunity system is significant and one can support that through NK Cell Therapy.

What is NK cell therapy?

NK cell is a type of white blood cell. NK cell therapy starts from taking a blood sample. Next, NK cells are separated and cultured to raise their potential. NK cells are then reinfused back into the body to support the function of other immune cells.

With better functioning NK cells, the immune system becomes stronger. Patients become less susceptible to infection and the elimination of cancer cells improves. In addition, the intercommunication between white blood cells improve both the immune response and metabolism.


Mistletoe is one of the most widely studied complementary and alternative medicine therapies for cancer. Recent years have seen growth in the number and quality of clinical research studies on mistletoe therapy reporting improved patient outcomes, including studies of its co-administration alongside chemotherapy to reduce adverse effects and to improve quality of life in many cancer patients.

Viscum album is a species of mistletoe that occurs predominantly in central Europe, growing as a semi-parasitic plant on various host trees such as apple, oak, pine, elm, maple, and birch.

Extracts from Viscum album have been used since decades in complementary cancer therapy. They contain various substances with biologic activity (mistletoe lectins (ML)), of which ML have been found most interesting. Mistletoe extracts and ML have shown to possess distinct cytotoxic effects on a panel of 38 cancer cell lines.

Mistletoe products vary, depending on the following factors:

  • The type of host tree on which the mistletoe grows.
  • The species of mistletoe
  • The type of extract used and if it is made with homeopathic methods
  • The time of year the plant is picked
  • The company that makes the product


  • Cytotoxic effect: Mistletoe is potential anti-cancer agent as extracts derived have been shown to kill cancer cells and regulate central genes involved in tumour progression, malignancy plus cell migration and invasion.
  • Anti-inflammatory effect: Bioactive phytochemicals are able to act as natural immunomodulators. Recent observations of a potent anti-inflammatory effect provide a further rationale for an anti-tumour role of mistletoe in view of the close relationship between cancer and inflammation. 
  • Immunomodulation: Mistletoe therapy is among the most frequently used integrative oncological drugs in several countries in Europe. This therapy has been proven to increase health related quality of life and the reduction of adverse effects associated with conventional anti-cancer approaches.
  • Application: Mistletoe are usually given by subcutaneous injection, although administration by other routes (i.e. oral, intrapleural, intra-tumoral and intravenous) are also viable.

Adverse effects:

Although a number of different mistletoe extracts have been used in human studied, the reported side effects have generally been minimal and not life threatening.

Common side effects include soreness and inflammation at injection sites, headache, fever and chills.

Another reported adverse reaction may include increase intracerebral pressure, circulatory problems, thrombophlebitis, swelling of lymph nodes and allergic reactions.  However, no immunosuppressive effects were reported.

In general, Mistletoe therapy may assist in the elimination of cancerous cells and at the same time lowers the adverse effects of conventional treatments. This in turn can bring about positive domino effect on a sufferer’s quality of life.  Patients are therefore able to better tolerate the cancer treatments bringing about patient compliance which can lead to better clinical outcomes.


GcMAF is a type of protein that has an important function in stimulating the immune system and destroying various cancer cells. This is done by stimulating the type of white blood cells known as Macrophage, which is a type of white blood cells that work to catch and eat foreign bodies such as viruses, bacteria and various germs.

This type of white blood cells are found both in the blood and in various tissues. But they are generally found in tissues, especially in those tissues that are infected by cancer.

Some early studies suggest that it may be helpful for people with late-stage cancers. Researchers tested the GcMAF on people with breast, colorectal, and prostate cancers who had undergone a combination of conventional cancer treatment.

The patients were given a small dosage of GcMAF on a weekly basis. All of the patients were cured, after a few months of going through the treatment protocol. The patients were then observed for a period of 4 to 7 years and results are impressive. The cancer had not come back within the period of observation.

Therefore, GcMAF with a combination of conventional approach through the Integrative Medicine pathway may be the key to one’s battle against cancer.

Dendritic cells

According to many clinical studies, Dendritic cells (DCs) have unique characteristics that have made them an ideal choice for anti-tumor vaccines.

They are considered to be the most effective antigen-presenting cell that is responsible for primarily sensitizing naive T-cells to a specific antigen. DCs are ten to 100 times more potent than B cells and monocytes. In addition, DCs play an important role in the establishment of immunologic memory which is a key factory to the anti-cancer efficiency.

In contrast with monocytes and B cells, DCs has the capacity to use soluble protein antigens to sensitize naive T-cells in vitro. Using these soluble proteins, DCs have successfully sensitized both CD8 and CD4that are T-cells inducing antigen-specific cytotoxic T lymphocytes.

The above ability gives scientists developing these DC-based vaccines a variation of potential antigen agents that are highly effective in sensitizing T-cells. With regards to fighting cancer, there are many testimonies and evidence-based studies that prove the ability of DCs on being one of the key success factor in destroying tumor cells.

Benefits DC vaccine

Generally, dendritic cell therapy can bring about the following benefits and further boost anti-cancer functions:

  • Boosting of immunity
  • Enhancing the migration function of the T-cells
  • Increase the longevity of the T-cells
  • Improve cytokine creation

The treatment

In this treatment, the patient’s blood will firstly be extracted followed by the cells. These cells are then cultured into DC and different types of cancer antigens are then added to a vaccine that has anti-cancer properties.

The DC vaccine is injected or reintroduced into the body helps boost the immune function. The T cells are able to better detect and destroy cancer cells. It has the ability to teach the white blood cells to recognize and defeat these cancer cells and pathogens making Dendritic cell or DC vaccine a formidable asset in the fight against cancer.

Interleukin 2 (IL2)

Cancer strikes anxiety and fear in the minds of many. Nowadays, Cancer is known to be one of the most common lethal disease in the world. However, recently there has been a breakthrough in harnessing the immune system to treat malignant tumors.

Cytokines are small glycoproteins that bind to cell surface receptors and regulate the development, survival and function of the immune cell. Therefore, cytokines have been extensively studied as potential therapeutic agents to manipulate the immune response to tumor cells.

Interleukin 2 (IL-2) is one of the key cytokines with pleiotropic effects on the immune system. Interleukin 2 (IL-2) is required for the activation, growth and differentiation of several families of immune cells which includes, T lymphocytes, B lymphocytes and the natural killer (NK) cells.

Currently, the main indication of Interleukin 2 (IL-2) includes the treatment of metastatic renal cell carcinoma and melanoma for which high-dose intravenous regimens comes highly recommended.

The application of IL2 in cancer immunotherapy

IL-2 was the first cytokines to be successfully used in the treatment of cancer. This was because it can promote T cells as well as NK cells. IL-2 can induce T cell proliferation and differentiation and also cause its activation.


With chemotherapy

 Large trials on bio-chemotherapy involving a combination of chemotherapeutic agent with IL-2. Several large trials on metastatic melanoma have consistently shown better overall response rates with early clinical benefit as compared to standalone chemotherapy.


With targeted therapy

Targeted therapy has deeply revolutionized the current strategy for cancer treatments and management. This is especially after the discovery of BCR-ABL in leukemia and EGFR mutation in non-small-cell lung cancer (NSCLC). The role of IL-2 activation in the restoration of the immune-competence of lymphocytes against lung cancer has been positively demonstrated. EGFR-TKI affects the cancer-related networks of pro-inflammatory cytokines and activates the lymphocytic responses. This shows a possible synergy between the EGFR molecular pathway inhibition and immune system modulation in tumor shrinkage.


Safety considerations

 For subcutaneous injections, minor toxicities were observed including fatigue, transient fever and digestive disorders. Patients can develop transient subcutaneous nodules at the injection sites. These side effects never required hospitalization nor discontinuation of therapy. A dose-dependent and sustained increase in peripheral blood eosinophils and lymphocytes was observed.



In conclusion, Cancer is no longer a death sentence. There are several ways to prevent, manage and even cure this disease that is rapidly increasing in prevalence. Knowing and understanding the disease can help one take preventive steps or choose the best curative path.


RIGVIR is one of the many cancer treatments that uses a special virus that is aimed at infecting only the cancer cells while not affecting any normal cells. This antiviral therapy is registered and approved for the treatment of cancer and had been registered in Latvia since 2004.

Supporting the immune system

RIGVIR belongs to the group of medication called immunomodulators. RIGVIR is a type of virus based immunomodulator with proven anti-tumor response for the treatment of melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of cancer relapse and post-surgery metastases.
It is also a live, non-pathogenic substance that has not been genetically modified. Additional facts are as follows:

  • Selectively infects tumor cells
  • It is a safe and effective form of cancer treatment
  • Improves progression time, overall survival and the quality of life for cancer patients.
  • It is well tolerated
  • Causes no if any serious adverse effects
  • Has oncolytic and oncotropic properties (more information found below)

How it works

RIGVIR finds and infects tumor cells in a process is called oncotropism. It is able to replicate in tumor cells and effectively destroying them through a process called oncolysis. Both of the processes mentioned only selectively affects cancerous cells and Does Not or has very minimal effect on healthy cells.


According to Journal of Cancer on, the results suggest that RIGVIR invitro reduces the viability of cells of human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma and several others.

The presence of RIGVIR in the sensitive cells was confirmed using anti-specific antibodies. It has been proven that the cytolytic properties it possesses brings about clinical benefits. The Integrative Medicine approach believes that in combination with other interventions, RIGVIR can bring about positive treatment outcomes.


Send Inquiry

Ask about our treatments

Call Us

+66 (0) 655 896 964




About Us

About Akesis Life

Our Medical Team

Vision / Mission

Absolute health group


Contact Us

Send Inquiry

Find a Doctor

Medical Articles

Health & Wellbeing




Patient Guide

Medical Centre

Payment Options

Accommodation and Facilities

Training & Workshop

AKESIS LIFE : Integrative Oncology
21 Fl., 253 Asoke Building, Sukhumvit 21 Road, Klongtoey-Nua, Wattana, Bangkok 10110